Epithelioid Haemangioendothelioma Observational Study

Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Nov 6, 2024

Keywords

ClinConnect Summary

The Epithelioid Haemangioendothelioma (EHE) Observational Study is a clinical trial designed to learn more about a rare type of cancer called EHE. Researchers are interested in understanding how this disease presents itself, how it progresses over time, and the outcomes of different treatments. The study aims to identify specific substances in the body, known as biomarkers, that could help in developing new therapies. Participants will help create models to test potential treatments and discover new targets for therapy.

To be eligible for this study, participants must have a confirmed diagnosis of EHE based on specific guidelines, and they need to provide their consent to join the study. There is no age limit, so anyone diagnosed with EHE can participate as long as they can follow the study's requirements. Those who join can expect close monitoring and support throughout the study, contributing valuable information that could improve future treatments for EHE.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological diagnosis of EHE according to 2020 WHO classification, performed on biopsy or surgical specimen
• • Signed informed consent
• • Adequate patient compliance to treatment or follow up
• • No age limit
• Exclusion Criteria:
• • Impossibility to ensure adequate compliance